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Abstract  
Background 
Identifying disease causing genes and understanding their molecular mechanisms are 
essential to developing effective therapeutics.  Thus, several computational methods 
have been proposed to prioritize candidate disease genes by integrating different data 
types,  including  sequence  information,  biomedical  literature,  and  pathway 
information.    Recently,  molecular  interaction  networks  have  been  incorporated  to 
predict disease genes, but most of those methods do not utilize invaluable disease-
specific information available in mRNA expression profiles of patient samples. 
Results 
Through the integration of protein-protein interaction networks and gene expression 
profiles  of  acute  myeloid  leukemia  (AML)  patients,  we  identified  subnetworks  of 
interacting proteins dysregulated in AML and characterized known mutation genes 
causally implicated to AML embedded in the subnetworks. The analysis shows that 
the  set  of  extracted  subnetworks  is  a  reservoir  rich  in  AML  genes  reflecting  key 
leukemogenic processes such as myeloid differentiation,   
Conclusion 
We showed that the integrative approach both utilizing gene expression profiles and 
molecular  networks  could  identify  AML  causing  genes  most  of  which  were  not 
detectable with gene expression analysis alone due to their minor changes in mRNA.  
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Background  
Mining disease-causing genes and elucidating their pathogenic molecular mechanisms 
are of great importance for developing effective diagnostics and therapeutics [1-5].  
Along with many genetic and genomic studies aimed at identification of disease genes 
(e.g.  linkage  analysis,  cytogenetic  studies,  microarray  experiments,  proteomic 
studies), several computational methods have been proposed to prioritize candidate 
genes  based  on  various  information  including  sequence  similarity,  literature 
annotation,  and  molecular  pathways  [6-11].  Given  a  set  of  genes  known  to  be 
involved  in  disease,  these  methods  typically  score  similarities  between  candidate 
genes and known disease genes in terms of various genomic features.  
 
Recently,  accumulated  knowledge  about  molecular  interaction  networks  in  human 
cells  such  as  protein-protein,  and  protein-DNA  interactions  has  been  utilized  to 
predict  disease  genes  [6-8,  10,  12-14].    The  previous  studies  have  incorporated 
topological characteristics of known disease genes such as degrees in networks [14], 
the  overlap  between  interaction  partners  of  candidate  genes  and  those  of  known 
disease genes [6], the probability of candidate genes to participate in the same protein 
complexes with known disease-causing genes [10], or the distribution of distances 
from candidate genes to known disease genes [13].   
 
Despite their successful performance in general, for some specific diseases of our 
interest, such as acute myeloid leukemia (AML), the performance is not satisfactory 
(AUC = 0.55 by Radivojac et al. [13]).  We hypothesized that integrating molecular 
networks with mRNA expression profiles from patients might help delineate disease-
specifically dysregulated molecular subnetworks containing disease-causing mutation 
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genes.  Chuang et al. supported this hypothesis  showing the identified subnetworks 
included significantly enriched known breast cancer mutation genes [15].  Mani et al. 
proposed another method predicting oncogenes in B-cell lymphomas integrating both 
molecular interactions and mRNA expressions [16].   
 
Here, we identified molecular subnetworks dysregulated in AML patients which were 
associated with key leukemogenic processes such as myeloid differentiation. We also 
evaluated  the  enrichment  of  known  AML-causing  mutation  genes  within  the 
subnetworks, and the results show that the subnetworks contain significant fraction of 
known  AML  genes  (mostly  non-differentially  expressed)  embedded  among  the 
interconnections of differentially expressed genes. In addition, several characteristics 
of AML  genes in the subnetworks explored in this study  can be utilized to build 
prediction models for unknown AML genes.  
 
Results and Discussion 
Identification of subnetworks perturbed in AML 
The method to find subnetworks of AML is similar to that of our previous work [15], 
and visualized in Figure 1.  We overlaid the gene expression values of each gene on 
its corresponding protein in the protein-protein and protein-DNA interaction network  
and searched for subnetworks whose combined activities across the patients have high 
perturbation  scores  (PS)  starting  from  each  node  in  a  greedy  fashion.  The  gene 
expression profiles used cDNA platforms where each expression value of gene gi in 
patient pj (gij) is the mean log ratio of intensities from Cy5-labeled mRNA of the 
patient and Cy3-labeld reference mRNA. Expression values were normalized for each 
gene across patients to have mean 0 and standard deviation 1 (zij). We took absolute 
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values of expression levels to measure perturbation effect regardless of the direction 
of changes (i.e. up or down). The perturbation score was defined as the mean over 
standard  deviation  of  an  activity  vector  across  samples  whose  activity  values  are 
averaged gene expression levels of genes participating in each subnetwork Mk and is 
denoted as S(Mk) in Figure 1. Subnetworks with higher mean and smaller variance of 
activity levels are considered more perturbed in AML samples. 
 
AML subnetworks associated with key leukemogenic processes. 
Through the search for sutnebworks perturbed in AML patients, we identified 269 
subnetworks (p<0.05) comprising of 859 genes whose functions are associated with 
AML development processes such as myeloid differentiation, cell signaling of growth 
and  survival,  cell  cycle,  cell  and  tissue  remodeling.  Within  the  significant  AML 
subnetworks, we found many of already known AML-causing mutation genes. Figure 
2  shows  examples  of  subnetworks  containing  known  AML  genes  such  as  JAK2, 
JAK3,  PDGFRB,  and  CREBBP,  and  their  representative  biological  processes. 
Especially, a severe block in myeloid differentiation is known to be the hallmark of 
AML.  
 
AML subnetworks enriched for known AML causing genes. 
We have evaluated the enrichment of known AML genes in significant subnetworks 
in a systematic way. We compiled 62 genes known to be causally mutated in AML 
from Sanger Cancer Gene Census. 150 out of 269 subnetworks included at least one 
AML  gene, and 49 subnetworks included two or more AML  genes. As shown in 
Figure  3,  subnetworks  were  much  more  significantly  enriched  for  AML  causing 
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mutation  genes  than  the  conventional  gene-expression  analysis  alone  without 
considering molecular interactions (p value P = 7.14e-6 vs. P = 0.04). 
 
Characterstics of AML genes in the subnetworks. 
Table 1 lists 18 known AML genes detected in perturbed subnetworks along with the 
number of subnetworks including a designated gene and the magnitude of differential 
expression in its mRNA level (DES) for each gene. JAK3, KIT, EVI1, and CREBBP 
appeared  in  more  than  10  subnetworks  while  other  genes  were  present in  two  or 
mostly one subnetwork.  JAK3 with the extremely high frequency (110) has been 
reported to have great biological importance in AML pathogenesis through gain-of-
function  JAK3  mutations  (e.g.  JAK3A572V,  JAK3V722I,  JAK3P132T)  activating 
signal transduction [17].  Mutations in KIT having the second highest frequency (43) 
were  also  found  in  more  than  30%  of  patients  with  de  novo  AML  [18].  The 
appearance frequency of an AML gene in subnetworks is more correlated with the 
magnitude  of  its  DES  score  (correlation  coefficient r  =  0.43)  than  the number  of 
interacting partners, the node degree (r = 0.01). 
 
We examined whether AML genes captured in subnetworks have high degrees in the 
network because that property has been used to predict unknown disease genes in 
other diseases previously (Figure 4a). The figure shows that all known AML-causing 
genes  (AML)  and  AML  genes  captured  in  subnetworks  (AML_Network)  have 
significantly more interaction partners than all genes in the network (P = 1.22e-6, and 
P = 2.34e-6, respectively). AML genes found in subnetworks have slightly higher 
degree  than  AML  genes  not  captured  in  subnetworks  (P  =  0.02).  The  mean  and 
median degrees of all genes in the network are 9 and 4, while those of 18 AML genes 
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are 51 and 27. Though this result supports that known AML genes have tendency of 
high  network  degrees,  low  degree  AML  genes  such  as  RPL22,  and  TRIP11  also 
appeared in the subnetworks. 
 
Finally, we investigated the differential expression of AML genes in mRNA levels 
(Figure 4b). There was no significant difference between each group of genes, and all 
known AML genes and those found in subnetworks except FLT3, and JAK3 did not 
show mRNA level aberrations. This result shows that gene expression alone does not 
provide  enough  information  to  predict  unknown  AML-causing  mutation  genes. 
However, our integrative approach could capture non-differentially expressed AML 
genes  in  subnetworks  if  they  were  entangled  with  neighbour  proteins  whose 
expressions are differentially expressed resulting subnetworks with high perturbation 
scores. 
  
Conclusion 
We have demonstrated that integration of condition-independent molecular networks 
extracted from various types of cells and experiments under different conditions, and 
disease-specific mRNA expression profiles of AML patients enables the dissection of 
pathogenic modules of interacting proteins reflecting key leukemogenic processes. In 
addition, the dissected modules are enriched for AML-causing mutation genes most of 
which are not detectable with gene expression analysis alone due to minor changes in 
their  mRNA  levels.  Identification  of  subnetworks  perturbed  in  AML  patients  can 
provide  novel  molecular  hypotheses  underlying  AML  etiology,  and  investigated 
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characteristics of known AML genes appearing in the subnetworks can be exploited to 
predict unknown AML-causing genes.  
 
Methods 
 
Protein-protein interaction networks.  
We downloaded the PPI network from the PhenoPred website by Radivojac et al. 
[19].  It consists of 41456 physical interactions among 9142 proteins assembled from 
Human  Protein  Reference  Database  (HPRD)  [20],  The  Online  Predicted  Human 
Interaction Database (OPHID) [21], and studies by Rual et al. and Stelzl et al. [22, 
23]. 
 
mRNA expression profiles of AML patients.  
Gene  expression  profiles  of  65  peripheral-blood  samples  and  54  bone  marrow 
specimens from 116 adult patient with AML were downloaded from Gene Expression 
Omnibus  (GSE425)  whose  expression  values  are  log  ratios  (base  2)  of  mean 
intensities of patient samples vs. common reference mRNA [24]. Gene identifiers of 
three cDNA microarray platforms (GPL317,318,319) were mapped to gene symbols 
using accompanied gene annotation files from GEO yielding 6987 gene symbols with 
expression levels in at least one of three platforms. 
 
Mutation genes in AML patients. 
We  compiled  two  sets  of  AML-associated  genes:  14  genes  downloaded  from 
PhenoPred  web  site  originally  collected  from  OMIM  [25],  Swiss-Prot  [26],  and 
HPRD [20] by Radivojac et al. (Disease Ontology ID: 9119) [19], and  62 genes 
whose  somatic  and  germline  mutations  are  causally  implicated  in  AML  patients 
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downloaded from Sanger Cancer Gene Census [27], and also appearing in our PPI 
network. 
 
Significance evaluation of subnetworks.  
To evaluate the significance of the identified subnetworks, we performed the same 
search  procedure  over  1000  random  trials  in  which  the  expression  vectors  of 
individual genes are randomly permuted in the network. The p value of each real 
subnetwork is calculated as the fraction of random subnetworks having higher PS 
scores  than  the  designated  real  subnetwork  among  all  random  subnetworks.  We 
consider subnetworks with the p-value P < 0.05 significant in this work 
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Figures 
Figure 1. Schematic overview of the subnetwork identification. 
Schematic overview of the subnetwork identification. The mRNA expression levels of 
each gene were overlaid on its corresponding protein in the network and subnetworks 
whose  combined  activities  across  the  patients  have  high  perturbation  score  were 
searched.  An activity level (akj) for a subnetwork Mk in j
th sample was defined as the 
mean expression levels with the square-root of the number of participating genes in 
the denominator. The perturbation score S(Mk) for the subnetwork was then calculated 
as the mean over the standard deviation of the activity levels across patients. 
 
Figure  2.  Examples  of  subnetworks  containing  known  AML  mutation 
genes.  
Nodes and links represent human proteins and protein interactions, respectively. The 
color of each node shows the degree of mRNA level change in AML patients. Known 
AML mutation genes are marked with the diamond shape. 
 
Figure 3. The enrichment of AML mutation genes in subnetworks.  
18 out of 62 AML genes (29.03%) were found in 269 subnetworks including 859 
genes,  and  their  enrichment  was  significant  (p-value  P  =  7.14e-6)  through  the 
hypergeometric test (the probability of 18 AML genes out of all 62 are found in the 
subnetworks including total 859 genes out of 9142 genes in the whole network). In 
contrast, only two AML genes (FLT3, JAK3) (3.23%) were found among 859 top 
differentially expressed genes in their mRNA levels (P = 0.04) 
Page 10 of 19  - 11 - 
Figure 4. (a) Degrees and (b) mRNA expression changes of AML genes  
Each figure shows node degrees and magnitudes of differential expression (DES) for 
AML-causing  mutation  genes  found  in  subnetworks  (AML_Network),  all  known 
AML mutation genes (AML), and all genes in the whole network. The bottom and top 
of each box are first and third quartiles, and the band near the middle of the box is the 
median. Whiskers extend to at most 1.5 times the inter-quartile range. Beyond the 
whiskers,  all  outliers  are  shown  in  open  circles.  The  statistical  significances  for 
differences  between  two  groups  of  genes  (e.g.  AML_Network  vs.  All  genes) 
measured by non-parametric Wilcox rank-sum test are denoted below the labels of 
gene groups. 
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Tables 
Table 1  - AML mutation genes in subnetworks 
Genes  Number of 
Subnetworks  Degree  DES
+ 
JAK3
*  110  32  2.73 
KIT  43  54  1.97 
EVI1  16  7  -1.27 
CREBBP  14  209  1.5 
EP300  7  216  2.36 
BCR  2  32  1.41 
FLT3
**  2  11  3.58 
NSD1  2  6  1.14 
PTPN11  1  109  -1.07 
JAK2  1  87  N/A 
PDGFRB  1  56  -0.33 
NPM1  1  33  -0.37 
RUNX1  1  22  0.68 
GATA2  1  20  1.58 
PICALM  1  8  0.44 
FNBP1  1  7  2.05 
RPL22  1  3  1.08 
TRIP11  1  2  -1.29 
+DES means the degree of change in its mRNA level for each gene. 
Genes having top 5% and higher absolute PS scores are marked with **, and 
top 10% and higher with *. 
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